Human recombinant erythropoietin therapy;Tratamiento con eritropoyetina humana recombinante

Medicina

Volumn 66, Issue 1, 2006, Pages 51-69

  Donato, Hugo ^a,c   Ferro, Hugo ^b  

^a Sanatorio de la Trinidad   (Argentina)

^b Clinica y Maternidad Suizo Argentina   (Argentina)

^c NONE   (Argentina)

Author keywords

Anemia of prematurity; Cancer; Erythropoietin; Hemolytic uremic syndrome; HIV infection; Neuroprotection; Renal failure

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ZIDOVUDINE;

ANEMIA; BLOOD TRANSFUSION; CHILD CARE; DISEASE ASSOCIATION; DONOR; DRUG EFFICACY; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MEDICAL RESEARCH; PRACTICE GUIDELINE; PREMATURITY; REVIEW; SAMPLE SIZE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANEMIA; ANEMIA, NEONATAL; CHILD; CHILD, PRESCHOOL; ERYTHROPOIETIN, RECOMBINANT; HEPATITIS C; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, POSTMATURE; KIDNEY FAILURE; NEOPLASMS; RENAL DIALYSIS;

EID: 33645167045     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (202)

1. Krantz SB. Erythropoietin. Blood 1991; 77: 419-25.
2. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003; 228: 1-14.
3. Dame C, Juul SE. The switch from fetal to adult erythropoiesis. Clin Perinatol 2000; 27: 507-26.
4. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG. Assignment of the hypoxia-inducible factor 1alfa gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics 1996; 34: 437-9.
5. Kaelin WG Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 2003; 14: 2703-11.
6. Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000; 27: 681-96.
7. Zanjani ED, Pixley JS, Slotnick N, et al. Erythropoietin does not cross the placenta into the fetus. Pathobiology 1993; 61: 211-5.
8. Campbell J, Wathen N, Lewis M, et al. Erythropoietin levels in amniotic fluid and extraembryonic coelomic fluid in the first trimester of pregnancy. Br J Obstet Gynaecol 1992; 99: 974-6.
9. Koury ST, Koury MJ. Erythropoietin production by the kidney. Semin Nephrol 1993; 13: 78-86.
10. Dame C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998; 92: 3218-25.
11. Muta K, Krantz SB, Bondurant MC, et al. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1994; 94: 34-43.
12. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-64.
13. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 92: 7850-84.
14. Esbach JW, Egrie JC, Downing MT, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
15. Gimenez LF, Scheel PJ. Clinical application of recombinant erythropoietin in renal dialysis patients. Hematol Oncol CI NA 1994; 8: 913-26.
16. Scigalla P. Effect of recombinant human erythropoiein treatment on renal anemia and body growth of children with end-stage renal disease. En: Baldamus CA, Scigalla P, Wieczorek L, et al (eds). Erythropoietin in renal and non-renal anemias. Basel: Kargel, 1991.
17. Rendo P, Biscigniano L, Turconi A, Sánchez Avalos JC, Greco J. Tratamiento cle la anemia en niños sometidos a hemodiálisis crónica con eritropoyetina humana recombinante. Medicina (Buenos Aires) 1994; 54: 392-98.
18. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2: ii1-50.
19. National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001; 37: S182-238.
20. Jabs K, Alexander S, McCabe D. Primary results from the U.S. multicenter pediatric recombinant eryhropoiein (epo) study. J Am Soc Nephrol 1994; 5: 456.
21. Port RE, Kiepe D, Van Guilder M, Jellife RW, Mehls O. Recombinant human erythropoietin for the treatment of renal anaemia in children. Clin Pharmacokinet 2004; 43: 57-70.
22. Cusumano A, Rendo P, Macheroni C, Sánchez Avalos JC. Tratamiento cle los pacientes en hemodiálisis crónica (HDC) con dosis bajas de eritropoyetina recombinante (r.Hu EPO) asociada o no a andrógenos. Nefrología 1996; 16: 374-8.
23. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-85.
24. Macdougall IC, Steering Committee of the CREATE trial, CREATE Study Group. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 2003; 18 (Suppl 2):ii13-16.
25. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
26. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58:1325-35.
27. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15:1425-30.
28. Macdougall IC. Optimizing the use of erythropoietic agents-pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 (Suppl 5): 66-70.
29. Barre P, Reichel H, Suranyi MG, Barth C. Efficacy of once-weekly epoetin alfa. Clin Nephrol 2004; 62: 440-8.
30. Frifelt JJ, Tvedegaard E, Bruun K et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int 1996; 16: 594-8.
31. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61:392-405.
32. Jones CH, Ridley L, Richardson D. Which EPO dose per week? Nephrol Dial Transplant 2002; 17: 1855.
33. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-33.
34. Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 2004; 19: 662-6.
35. Schroder CH, The European Pediatric Peritoneal Dialysis Working Group. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol 2003; 18: 805-9.
36. Piraino B, Johnston JR. The use of subcutaneous erythropoietin in CAPD patients. Clin Nephrol 1990; 33: 200-11.
37. Saito S, Fujiwara T, Sakagami K, Matsuno T, Tanaka N. Anemia following renal transplantation. Transplant Proc 1998; 30: 3025-6.
38. Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40: 1306-18.
39. Al-Uzri A, Yorgin PD, Kling PJ. Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003; 7: 253-64.
40. Nielsen OJ, Thaysen JH. Erythropoietin deficiency in acute renal failure. Lancet 1989; 1: 624-5.
41. Fernández V, Campbell M, Itscoff P, et al. Deficit relativo de EPO endógena en anemia por IRA. Nefrología 1992; 12 (Supp] 2): 64.
42. Exeni R, Donato H, Rendo P, et al. Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome. Pediatr Nephrol 1998; 12: 226-30.
43. O'Brien MER, Casey S, Treleaven J, Powles TJ. Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/ tamoxifen. Eur J Cancer 1994; 30: 894-5.
44. Catalano C, Gianesini C, Fabbian F. Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome. Nephron 2002; 91: 324-6.
45. Citarrella P, Gebbia V, Teresi M, et al. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report. Anticancer Res 2002; 22: 1183-5.
46. Ellis D. Anemia in the course of the nephrotic syndrome secondary to transferrin depletion. J Pediatr 1977; 90: 953-5.
47. Feinstein S, Becker-Cohen R, Algur N, et al. Erythropoietin deficiency causes anemia in nephrotic childen with normal kidney function. Am J Kidney Dis 2001; 37: 736-42.
48. Rifkin D, Kravetz HM, Knight V, Schade AL. Urinary excretion of iron-binding protein in the nephrotic syndrome. N Engl J Med 1961; 265: 115-8.
49. Hancock DE, John W, Onstad JW, Wolf PL. Transferrin loss into the urine with hypochromic, microcytic anemia. Am J Clin Pathol 1976; 65: 73-8.
50. Vaziri ND, Kaupke CJ, Barton CH. Gonzales E. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 1992; 92: 35-40.
51. Zhou KJ, Vaziri ND. Erythropoietin metabolism and pharmacokinetics in experimental nephrosis. Am J Physiol Renal Physiol 1992; 263: F812-5.
52. Gansevoort RT, Vaziri ND, De Jong PE. Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Am J Kidney Dis 1996; 28: 274-7.
53. Ishimitsu T, Ono H, Sugiyama M, et al. Sucessful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron 1996; 74: 607-10.
54. Bayés B, Serra A, Juncá J, Lauzurica R. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropietin. Nephrol Dial Transplant 1998; 13: 1894-5.
55. Donato H, Vain N, Rendo P. Tratamiento con eritropoyetina humana recombinante en período neonatal: indicaciones y controversias. Arch Arg Pediatr 1996; 94: 28-45.
56. Garby L, Sjolin S, et al. Studies on erythrokinetics in infancy. III. Plasma dissapearance and red cell uptake of intravenously injected radioiron. Acta Paediatr 1963; 52: 537-40.
57. Dallman PR, Siimes MA. Percentile curves for hemoglobin and red cell volume in infancy and childhood. J Pediatr 1979; 94: 28-33.
58. Stockmann JA III, Graeber JE, Clark DA, et al. Anemia of prematurity: Determinants of erythropoietin response. J Pediatr 1984 105: 786-92.
59. Forestier F, Daffos F, Catherine N, Renard M, Andreux JP. Developmental hematopiesis in normal human fetal blood. Blood 1991; 11: 2360-3.
60. Yamashita H, Kukita J, Ohga S, et al. Serum erythropoietin levels in term and preterm infants during the first year of life. Am J Pediatr Hematol Oncol 1994; 16: 213-8.
61. Tan CC, Eckardt KU, Firth JD, et al. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992; 263: F474-81.
62. Frey B. Transfusion in premature infants impairs production and/or release of red blood cels, white blood cells and platelets. J Paediatr Child Health 2002; 38: 265-7.
63. Strauss RG. Transfusion therapy in neonates. Am J Dis Child 1991; 145: 904-11.
64. Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: Results of a randomized, placebo-controlled, multicenter trial. Pediatrics 2000; 105: 1066-72.
65. Yeo CL, Choo S, Ho L. Effect of recombinant human erythropoietin on transfusion needs in preterm infants. J Paediatr Child Health 2001; 37: 352-8.
66. Maier RE, Obladen M, Muller-Hansen I, et al. Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weight below 1000 g. J Pediatr 2002; 141: 8-15.
67. Lin JC, Strauss RG, Kulhavy JC, et al. Phlebotomy overdraw in the neonatal intensive care unit. Pediatrics 2000 106: e19-25.
68. Bifano EM, Curran TR. Minimizing donor blood exposure in the neonatal intensive care unit. Clin Perinatol 1995 22: 657-69.
69. Rhondeau SM, Christensen RD, Ross MP, et al. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the "anemia of prematurity". J Pediatr 1988; 112: 935-40.
70. Halperin DS, Wacker P, Lacourt G, et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. J Pediatr 1990 116: 779-86.
71. Shannon KM, Mentzer WC, Abels RI, et al. Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study. J Pediatr 1991 118: 949-55.
72. Ohls R, Christensen RD. Recombinant erythropoietin compared with erythrocyte transfusion on the treatment of anemia of prematurity. J Pediatr 1991; 119: 781-8.
73. Beck D, Masserey E, Meyer M, et al. Weekly intravenous administration of recombinant human erythropoietin in infants with the anemia of prematurity. Eur J Pediatr 1991; 150: 767-72.
74. George JW, Bracco C, Shannon K, et al. Response of Rhesus monkeys to recombinant human erythropoietin: Comparison of adults and infants. Pediatr Res 1989; 25: 269A.
75. Widness JA, Veng-Pedersen P, Modi NB, et al. Developmental differences in erythropoietin pharmacokinetics: Increased clearance and distribution in fetal and neonatal sheep. J Pharmacol Exp Therap 1992; 261: 977-84.
76. Messer J, Haddad J, Donato L, et al. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 1993; 92: 519-23.
77. Donato H, Rendo P, Vivas N, Schvartzman G, Digregorio J, Vain N. Recombinant human erythropoietin in the treatment of anemia of prematurity: A randomized, double-blind, placebo-controlled trial comparing three different doses. Int J Pediatr Hematol Oncol 1996; 3: 279-85.
78. Emmerson AJB, Coles HJ, Stern CMM, et al. Double blind trial of recombinant human erythropoietin in preterm infants. Arch Dis Child 1993; 68: 291-6.
79. Meyer MP, Meyer JH, Commerford A, et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study. Pediatrics 1994; 93: 918-23.
80. Shannon KM, Keith JF, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995; 95: 1-8.
81. Soubasi V, Kremonopoulos G, Diamandi E, et al. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatr Res 1993 34: 675-9.
82. Vamvakas EC, Strauss RG. Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematuriry. Transfusion 2001; 41: 406-15.
83. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial. J Pediatr 1995; 126: 421-6.
84. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infans weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr 1997; 131: 661-5.
85. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: A multicenter, randomized, controlled trial. Pediatrics 2001; 108: 934-42.
86. Kotto-Kome AC, García MG, Calhoun DA, Christenser RD. Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: A meta-analysis. J Perinatol 2004; 24: 24-9.
87. Ohls RK. Erythropoietin treatment in extremely low birth weight infants: Blood in versus blood out. J Pediatr 2002; 141: 3-6.
88. Ibojie J, Greiss M, Lloyd DJ, Urbaniak SJ. Donor exposure rate to transfusion ratio: a better discriminator of improvement in neonatal transfusion practice. Transf Med 2003; 13: 287-91.
89. Hilsenrath P, Nemechek J, Widness JA, Cordle DG, Strauss RG. Cost-effectiveness of a limited donor blood program for neonatal red cell transfusions. Transfusion 1999; 39: 938-43.
90. Brune T, Garritsen H, Hentschel R, Louwen F, Harms E, Jorch G. Efficacy, recovery, and safety of RBCs from autologous placental blood: clinical experience in 52 newborns. Transfusion 2003; 43: 1210-5.
91. Bifano EM, Dracker RA, Lorah K, Palit A. Collection and 28-days storage of human placental blood. Pediatr Res 1994; 36: 90-4.
92. Maier RF, Sonntag J, Walka MM, Liu G, Metze BC, Obladen M. Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g. J Pediatr 2000; 136: 220-4.
93. Donato H, Vain N, Rendo P. Folate and vitamin B12 supplementation in very low birth weight infants treated with erythropoietin: A cautionary note. Pediatrics 2002; 108: 218.
94. Pathak A, Roth P, Piscitelli J, Johnson L. Effects of vitamin E supplementation during erythropoietin treatment of the anaemia of prematurity. Arch Dis Child Fetal Neonatal Ed 2003; 88: F324-8
95. Zipursky A. Vitamin E deficiency anemia in newborn infants. Clin Perinatol 1984; 11: 393-402.
96. Millard DD, Gidding SS, Socol ML, et al. Effects of intravascular, intrauterine transfusion on prenatal and postnatal hemolysis and erythropoiesis in severe fetal isoimmunization. J Pediatr 1990; 117: 447-54.
97. Koenig JM, Ashton DR, De Vore GR, et al. Late hyporegenerative anemia in Rh hemolytic disease. J Pediatr 1989; 115: 315-8.
98. Ohls RK, Wirkus PE, Christensen RD. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease. Pediatrics 1992; 90: 678-80.
99. Scaradavou A, Inglis S, Peterson P, et al. Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: Use of erythropoietin to treat the late anemia. J Pediatr 1993; 123: 279-84.
100. Nenadov Beck M, Dessing C, Via] Y, Hohlfeld P. Efficacy of recombinant human erythropoietin (rHuEPO) in anemic neonates after intrauterine transfusions. J Pediatr Hematol Oncol 1999; 21: 333.
101. Ovali F, Samanci N, Dagoglu T. Management of late anemia in rhesus hemolytic disease: Use of recombinant human erythropoietin (A pilot study). Pediatr Res 1996; 39: 831-4.
102. Ovali F. Late anaemia in Rh haemolytic disease. Arch Dis Child Fetal Neonatal Ed 2003; 88: F444-6.
103. Nicaise C, Gire C, Casha P, d'Ercole C, Chau C, Palix C. Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion. Fetal Diagn Ther 2002; 17: 22-4.
104. Vaughan JL, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 338: 798-803.
105. Dhodapkar KM, Blei F. Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin. J Pediatr Hematol Oncol 2001; 23: 69-70.
106. Rendo P, Freigeiro D, Barboni G, Donato H, Drelichman G, Gonzalez A. A multicenter, randomized, double-blind trial with recombinant human erythropoietin (rHuEPO) in anemic HIV-infected children treated with antiretrovirals. Intern J Pediatr Hematol Oncol 2001; 7: 235-9.
107. Caselli D, Maccabruni A, Zucoti GV, et al. Recombinant erythropoietin for treatment of anaemia in HIV-infected children. AIDS 1996; 10: 929-31.
108. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S for the Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17: 2053-61.
109. Lux SE, Palek J. Disorders of the red cell membrane. En: Handin RI, Stosel TP, Lux SE (eds). Blood: Principles and Practice of Hematology. Philadelphia: J. B. Lippincot, 1995, p 1701-95.
110. Delhommeau F, Cynober T, Schischmanoff P, Rohrlich P, Delaunay J, Tchernia G. Hereditary spherocytosis during the first year of life: natural history and transfusion need. Blood 2000; 95: 393-9.
111. Tchernia G, Delhommeau F, Perrotta S, et al. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Hematol J 2001; 1: 146-52.
112. Kayemba-Kays's S, Christin P, Yahouanc-Lapalle H, Oriot D. Anémie néonatale par incompatibilité rhésus traitée par érythropoiétine. Arch Pediatr 2004; 11: 868-9.
113. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 2004; 116: 11S-26S.
114. Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol 2002; 39: 448-50.
115. Ludwig H, Barrett-Lee PJ, Gascon P, Scneider M, Van Belle S. European Cancer Anemia Survey (ECAS) defines factors surrounding anemia in thousands cancer patients. Proc Am Soc Clin Oncol 2002; 21: 387(a)
116. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004; 30: 563-75.
117. Bokemeyer C, Oechsle K, Hartmann JT. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 2002; 87: 1066-71.
118. Caro JJ, Salas M, Ward A. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. Cancer 2001; 91: 2214-21.
119. Aapro M, San Miguel J. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta. Oncology 2004; 67 (Suppl 1): 17-22.
120. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2004; Sept 27: (Epub).
121. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-25.
122. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
123. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
124. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218-34.
125. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003; 98: 1072-9.
126. Quirt I, Robeson C, Lau CY. Epoetin alfa in patients not on chemotherapy - Canadian data. Semin Oncol 2002 29: 75-80.
127. Quirt I, Robeson C, Lau CY. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy J Clin Oncol 2001; 19: 4126-34.
128. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, v.2.2004. Cancer and treatment-related anemia. Disponible en: http://www.enccn.com/professionals/physician_gls/PDF/anemia.pdf
129. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-107.
130. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201-16.
131. Rosberg J, Lefebvre P, Fastenau J. Clinical significance of a ≥1 gram/ deciliter (g/dL) rise in hemoglobin (Hb) at week 4 (early response) or at week 8 during epoetin alfa (EPO) treatment. Blood 2003; 102 (abstract 2777).
132. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21: 21-8.
133. Cella D, Zagari MJ, Vandoros C et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21: 366-73.
134. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's Lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446-53.
135. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122: 386-93.
136. Lastiri J M, Specterman S, Rendo P, Pallotta MG, Varela M, Goldztein S. Variables predictivas de respuesta a la eritropoyetina recombinante humana en pacientes con anemia y cáncer. Medicina (Buenos Aires) 2002; 62: 41-7.
137. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cáncer patients. Haematologica 2002; 87: 1209-21.
138. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 2003; 8: 99-107.
139. Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol 2002; 39: 463-8.
140. Parsons SK. Oncology practice patterns in the use of hematopoietic growth factors. Curr Opin Pediatr 2000; 12: 10-7.
141. Yilmaz D, Cetimgul N, Kantar M, Oniz H, Kansoy S, Kavakli K. A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 2004; 21: 1-8.
142. Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumours. Med Pediatr Oncol 2002; 39: 459-62.
143. Buyukpamukcu M, Varan A, Kutluk T, Akyuz C. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol 2002; 39: 455-8.
144. Kronberger M, Fischmeister G, Poertschger U, Gadner H, Zoubek A. Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr Hematol Oncol 2002; 19: 95-105.
145. Wagner LM, Billups CA, Furman WL, Rao NB, Santana VM. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 2004; 22: 1886-93.
146. Razzouk BI, Hockenberry M, Hinds PS, Feusner J, Rackoff W, Hord JD. Influence of hemoglobin response to epoetin alfa on quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. Blood 2004; 104: 609 (abstract 2218)
147. Bohlius J, Langensiepen S, Schwrzer G, et al. Erythropoietin for patients with malignant disease (Cochrane Review). En: The Cochrane Library, Issue 3. Chichester: John Wiley & Sons, 2004.
148. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
149. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-60.
150. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 2003; 42: 246-50.
151. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002; 82: 911-8.
152. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003; 83: 1477-87.
153. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021-29.
154. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301-8.
155. Belperio PS, Pharm D, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: A systematic review of the literature. Am J Med 2004; 116: 27S-43S.
156. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients across Europe. AIDS 1999; 13: 943-50.
157. Buskin SE, Sullivan PS. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion 2004; 44: 826-32.
158. Lundgren JD, Mocroft A, Gatelli JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis. 2002; 185: 178-87.
159. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med 1992; 117: 739-48.
160. Levine AM. Anemia in the setting of cancer and human immunodeficiency virus. Clin Infect Dis 2003; 37: S304-14.
161. Grossman HA, Goon B, Bowers P, Leitz G. 010 Study Group. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients, J Acquir Immune Defic Syndr 2003; 34: 368-78.
162. Saag MS, Bowers P, Leitz GJ, Levine AM; Community HIV Anemia Management Protocol Sites (CHAMPS) Study Group. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Res Hum Retroviruses 2004; 20: 1037-45.
163. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS. 2000; 11: 659-65.
164. Phair JP, Abels RI, McNeill MV, Sullivan DJ. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Ach Intern Med 1993; 153: 2669-75.
165. Balfour HH. Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine. Int J Antimicrob Agents 1997; 8: 189-92.
166. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1485-92.
167. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
168. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa mantains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.
169. Corwin HL, Surgenor SD, Gettinger A. Transfusion practice in the critically ill. Crit Care Med 2003 (Suppl): S668-71.
170. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288: 2827-35.
171. Juul SE. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol 2004; 31: 129-42.
172. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic tissue-protective cytokine. Cell Death Differ 2004; 11: S37-44.
173. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001; 79: 228-35.
174. Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res 2004; 1000: 19-31.
175. Cerami A. Beyond erythropoiesis: Novel applications for recombinant human erythropoietin. Semin Hematol 2001; 38: S33-9.
176. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004; 207: 3233-42.
177. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-51.
178. Buemi M, Allegra A, Corica F, et al. Intravenous recombinant
179. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. PNAS 2000; 97: 10526-31.
180. Juul SE, McPherson RJ, Farrell FX, Jollife L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 2004; 85: 138-44.
181. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
182. Kumral A, Ozer E, Yilmaz O, et al. Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 2003; 83: 224-8.
183. Sola A, Wen TC, Hamrick SEG, Ferriero DM: Potential for protection and repair following injury to the developing brain: a role for erythyropoietin? Pediatr Res 2005; 57: 110R-17R.
184. Calhoun DA, Christensen RD. Hematopoietic growth factors in neonatal medicine: the use of enterally administered hematopoietic growth factors in the neonatal intensive care unit. Clin Perinatol 2004; 31: 169-82.
185. Juul SE, Joyce AE, Zhao Y, et al. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr Res 1999; 46: 263-8.
186. Ledbetter DJ, Juul SE. Erythropoietin and necrotizing enterocolitis in the very low birth weight infant. Pediatr Surg 2000; 35: 178-82.
187. Britton J, Chistensen R. Enteral administration of recombinant erythropoietin to preterm infants. J Perinatol 1995; 15: 281-3.
188. Ballin A, Bilker-Reich A, Arbel E, Davidovitz Y, Kohelet D. Erythropoietin, given enterally, stimulates erythropoiesis in premature infants. Lancet 1999; 353: 1849.
189. Lima-Rogel V, Calhoun DA, Maheshwari A, et al. Tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors in neonates recovering from necrotizing enterocolitis. J Perinatol 2003; 23: 200-4.
190. Lewis LD. Preclinical and clinical studies: a preview of potential future applications of erythropoietic agents. Semin Hematol 2004; 41 (suppl 7): 17-25.
191. Cournoyer D, Toffelmire EB, Wells GA, et al. Canadian PRCA Focus Group.: Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15: 2728-34.
192. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-08.
193. Rossert J, Casadevall N, Eckardt KU: Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398-406.
194. Swanson SJ, Ferbas J, Mayeux P, Casadevall N: Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004; 96: c88-95.
195. Hoesel W, Gross J, Moller R, et al. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J Immunol Methods 2004; 294: 101-10.
196. Tacey R, Greway A, Smiell J, et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods 2003; 283: 317-29.
197. Mason S, La S, Mytych D, Swanson SJ, Ferbas J. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin. 2003; 19: 651-9.
198. Locatelli F, Aljama P, Barany P, et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant 2004; 19: 288-93.
199. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363: 1768-71.
200. Duffield JS, Mann S, Horn L, Winney RJ. Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia. Nephrol Dial Transplant 2004; 19: 479-81.
201. Snanoudj R, Beaudreuil S, Arzouk N, et al. Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation. Am J Transplant 2004; 4: 274-7.
202. Macdougall IC, Roche A, Rossert J, Casadevall N, Francois P, Kemeny DM. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant 2004; 19: 2901-5.